BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boukhaled GM, Harding S, Brooks DG. Opposing Roles of Type I Interferons in Cancer Immunity. Annu Rev Pathol 2021;16:167-98. [PMID: 33264572 DOI: 10.1146/annurev-pathol-031920-093932] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Kao K, Jaccard A, Ho P. IFNα Potentiates Immune-Checkpoint Blockade by Rewiring Metabolic Cross-talk. Cancer Discovery 2022;12:1615-6. [DOI: 10.1158/2159-8290.cd-22-0472] [Reference Citation Analysis]
2 Okada H, Takahashi K, Yaku H, Kobiyama K, Iwaisako K, Zhao X, Shiokawa M, Uza N, Kodama Y, Ishii KJ, Seno H. In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy. Sci Rep 2022;12:2132. [PMID: 35136110 DOI: 10.1038/s41598-022-05702-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Brown M. Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. Cancer Treat Res 2022;183:91-129. [PMID: 35551657 DOI: 10.1007/978-3-030-96376-7_3] [Reference Citation Analysis]
4 Leonardi L, Sibéril S, Alifano M, Cremer I, Joubert PE. Autophagy Modulation by Viral Infections Influences Tumor Development. Front Oncol 2021;11:743780. [PMID: 34745965 DOI: 10.3389/fonc.2021.743780] [Reference Citation Analysis]
5 Musella M, Galassi C, Manduca N, Sistigu A. The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. Biology (Basel) 2021;10:856. [PMID: 34571733 DOI: 10.3390/biology10090856] [Reference Citation Analysis]
6 Dekkers JF, Alieva M, Cleven A, Keramati F, Wezenaar AKL, van Vliet EJ, Puschhof J, Brazda P, Johanna I, Meringa AD, Rebel HG, Buchholz MB, Barrera Román M, Zeeman AL, de Blank S, Fasci D, Geurts MH, Cornel AM, Driehuis E, Millen R, Straetemans T, Nicolasen MJT, Aarts-Riemens T, Ariese HCR, Johnson HR, van Ineveld RL, Karaiskaki F, Kopper O, Bar-Ephraim YE, Kretzschmar K, Eggermont AMM, Nierkens S, Wehrens EJ, Stunnenberg HG, Clevers H, Kuball J, Sebestyen Z, Rios AC. Uncovering the mode of action of engineered T cells in patient cancer organoids. Nat Biotechnol 2022. [PMID: 35879361 DOI: 10.1038/s41587-022-01397-w] [Reference Citation Analysis]
7 Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol 2022. [PMID: 35697799 DOI: 10.1038/s41577-022-00737-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat Immunol 2022. [PMID: 35835962 DOI: 10.1038/s41590-022-01262-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sur D, Leonova K, Levi B, Markowitz SI, Cohen-harazi R, Gitlin I, Gurova K, Gudkov A, Pinhasov A, Koman I, Nesher E. Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition. IJMS 2022;23:7248. [DOI: 10.3390/ijms23137248] [Reference Citation Analysis]
10 Landelouci K, Sinha S, Pépin G. Type-I Interferon Signaling in Fanconi Anemia. Front Cell Infect Microbiol 2022;12:820273. [DOI: 10.3389/fcimb.2022.820273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 . Reactivity to type I interferon is key to predict cancer immunotherapy response. Nat Immunol 2022. [PMID: 35879452 DOI: 10.1038/s41590-022-01278-z] [Reference Citation Analysis]